Have you used a home testing kit for a medical diagnosis?

COVID-19 RATs are an example of these types of tests but we are interested in the many others on the market.

The University of Wollongong is conducting a small study about them and we'd like to hear from you if you have used one or considered using one.

Simply complete a short survey at:

From here, we may invite you to take part in a paid interview.

For more information, contact Dr Patti Shih: pshih@uow.edu.au

Take Survey Skip Survey

At a glance

Also known as

Breast cancer gene 1 and 2

Why get tested?

To assess the risk of developing breast or ovarian cancer associated with heritable genetic changes in the BRCA1 or BRCA2 genes


When to get tested?

Genetic testing may be offered by a specialist or consultant physician for a person with breast or ovarian cancer who meets certain criteria. The criteria for testing take several factors into consideration, such as the age at which the cancer was diagnosed, specific characteristics of the cancer, and whether other close family members have also been diagnosed with certain types of cancer previously. 

Genetic testing of an unaffected person is generally not performed unless a specific genetic fault (pathogenic variant) has already been identified in a family member.

Genetic testing of unaffected family members is offered only through a family cancer clinic. If an individual is referred to a family cancer clinic, the potential benefits, limitations, and possible consequences of genetic testing will be discussed prior to deciding whether to proceed..

Sample required?

A blood sample drawn from a vein in the arm

Confused about genetics?

See our Genetics Information page

What is being tested?

BRCA1 and BRCA2 are two tumour suppressor genes. Normally, these genes help prevent cancer by producing proteins that repair damage to DNA (the genetic material in a cell). Certain changes (pathgenetic variants) in these genes disrupt the function of the protein product and are associated with hereditary breast and ovarian cancers.

According to Cancer Australia, using statistics from the Australian Institute of Health and Welfare, over 19,000 women in Australia are diagnosed with breast cancer each year and about 1,500 women with ovarian cancer. In most of these women, their cancers are sporadic, but about 5-10% of these women have a familial predisposition to breast/ovarian cancer. Approximately 20% of the familial breast/ovarian cancers (i.e. 1-2% overall) are due to a genetic fault (pathogenetic variant) in the BRCA1 or BRCA2 gene.  Men can also inherit an increased risk of developing breast cancer, occasionally from pathgenetic variants in BRCA1, but primarily from pathgenetic variants in the BRCA2 gene.

The BRCA1 and BRCA2 genes are present in every cell of the body. To detect pathgenetic variants in these genes, DNA needs to be extracted from cells, and blood is the most easily accessible source of that DNA. 

How is the sample collected for testing?

BRCA 1/2 genetic testing is performed on a blood sample collected by needle from a vein in the arm. The test does not require surgical biopsy of breast or ovarian tissue.

The Test

How is it used?

There are thousands of different BRCA1 and BRCA2 genetic faults (pathgenetic variants) that have been reported. In familes with a strong family history of breast/ovarian cancer, it is usually necessary to first test an affected family member to determine whether the predisposition to breast/ovarian cancer in the family is due to a BRCA1/2 fault, and if so, what the particular fault (pathgenetic variant) is. This is known as diagnostic testing. Once the ‘familial variant’ is found, other family members can then be tested for that specific variant to determine their personal cancer risk. This is known as predictive (or pre-symptomatic) testing, and is only offered through a family cancer clinic.  Predictive (or pre-symptomatic) testing is helpful in deciding whether to take steps such as prophylactic surgery that may reduce the likelihood of developing breast or ovarian cancer in the future.

When is it requested?

If a BRCA1 or BRCA2 genetic fault (pathgenetic variant) has been identified in a family member with breast and/or ovarian cancer, then other family members can be tested for that specific variant to assess their risk.

Specific BRCA1 and BRCA2 variants are associated with some ethnic groups, such as those of Ashkenazi Jewish descent, and can be used to evaluate the risk of individuals in this group.

Someone who is considering testing should talk to their healthcare practitioner and seek genetic counselling by a genetics educator/counsellor prior to and after testing.

What does the test result mean?

The degree of risk conferred with a positive result is difficult to quantify for a specific person. Results must be interpreted in conjunction with the tested person's personal and family history. A genetic counsellor or familial cancer specialist should explain the meaning of the results, explain treatment options for the individual that are intended to decrease risk, and testing options for other family members.

The presence of a genetic fault (pathogenic variant) in BRCA1 or BRCA2 means that the person tested is at an increased risk for breast and/or ovarian cancer, but it does not mean that they will definitely develop cancer. Even within a family with the same BRCA1/2 variant, not everyone will develop cancer and those that do may develop it at different times during their life. The lifetime risk for breast cancer in women with a pathogenic BRCA1/2 variant is estimated to be up to about 70% (1). The risk of ovarian cancer is about 44% with a pathogenic BRCA1 variant and 17% with a pathogenic BRCA2 variant (1).

A negative result does not mean that an individual will not develop breast or ovarian cancer. It simply indicates that the person tested is not at increased risk for developing hereditary breast cancer or ovarian cancer related to the BRCA 1/2 variants for which he/she was tested. It is important to remember that more than 95% of breast cancers are not associated with a pathogenic BRCA1/2 variant. Furthermore, in the general population, the lifetime risk of developing breast cancer is approximately 12% and the lifetime risk of developing ovarian cancer is about 1%.

Is there anything else I should know?

Genetic testing of BRCA1 and BRCA2 cannot detect 100% of pathogenic variants in these genes; thus, even with a negative result there is a very small chance that there is a BRCA1/BRCA2 variant present that was not identified by the testing method utilised. For negative results, a genetic counsellor or specialist will provide tailored advice based on the individual’s personal and family history.

Genetic variants in other genes can also be associated with a familial risk for cancer so the specialist or consultant physician may offer testing of other genes besides BRCA1 and BRCA2. When deciding which genes to assess, the specialist will take into consideration factors such as the age at which the cancer was diagnosed, specific characteristics of the cancer, and whether other close family members have also been diagnosed with certain types of cancer previously.

Positive test results may have implications for other family members. When one member of a family is tested for BRCA 1/2 variants, issues often arise about how or whether to share this information with other family members. Seek advice from a genetic counsellor about communication of results with other family members.

Pre- and post-test consultation with a health care provider knowledgeable about genetic testing cannot be overemphasised. There are many issues to be considered when preparing for a genetic test and upon learning the results, and a genetic counsellor has the knowledge and expertise to help sort through them.

Common Questions

If the BRCA test is positive, what are my treatment options?

If the BRCA mutation test is positive, the options include more frequent cancer screenings and screening starting earlier in life (e.g., mammography, breast MRI, blood tests for CA-125 or CA 15-3, or transvaginal ultrasonography), medications that could reduce risk (e.g., tamoxifen), or surgical removal of the ovaries or breasts. There are a number of variables involved and it is important to discuss your options with your healthcare provider and genetic counsellor.

If the test is positive, how likely am I to get breast or ovarian cancer?

See the previous section "What does the test result mean?"

If the test is negative, how likely/unlikely am I to get breast or ovarian cancer?  

A negative result does not completely exclude the possibility of developing breast or ovarian cancer. See the previous section ‘What does the test result mean?’ for more information. 

Where can I get this test?

The test can be requested by specialists in familial cancer clinics or clinical geneticists if it is considered appropriate and should be accompanied by pre- and post-test genetic counselling. These services are available across Australia, and can be accessed by referral from your general practitioner. The blood sample will be sent to a laboratory that specialises in genetic testing.

Last Review Date: September 17, 2022

Was this page helpful?